Company intelligence / Profile preview
Sinopep-Allsino
Lianyungang, Jiangsu, Chinasinopep.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Sinopep-Allsino is a leading supplier of peptide APIs, especially for metabolic and endocrine indications. Notable programs like semaglutide have reached Phase 3, and several others are in IND or preclinical stages. The company has completed multiple FDA inspections and provides global-standard GMP API manufacturing.
- Therapeutic areas
- EndocrinologyInfectious DiseasesCardiovascularOncologyWomen's Health
- Modalities
- PeptidesSmall moleculeOligonucleotideSynthetic peptide
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Partner and API supplier for global pharma and biotech companiesExclusive API supplier for Albuvirtide and Lanreotide 505b2
Beyond the preview
Go deeper on Sinopep-Allsino.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sinopep-Allsino.